VASCUBONE
Construction kit for tailor-made vascularized boneimplants
| Coordinatore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 15˙569˙959 € |
| EC contributo | 11˙966˙071 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2015-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | coordinator | 2˙380˙655.59 |
| 2 |
JULIUS-MAXIMILIANS UNIVERSITAET WUERZBURG
Organization address
address: SANDERRING 2 contact info |
DE (WUERZBURG) | participant | 1˙816˙592.00 |
| 3 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 1˙172˙180.00 |
| 4 |
UNIVERSITETET I BERGEN
Organization address
address: Museplassen 1 contact info |
NO (BERGEN) | participant | 1˙082˙480.00 |
| 5 |
MRB Forschungszentrum fur Magnet-Resonanz-Bayern e.V.
Organization address
address: Am Hubland contact info |
DE (Wuerzburg) | participant | 898˙500.00 |
| 6 |
MEDICYTE GMBH
Organization address
address: Im Neuenheimer Feld 581 contact info |
DE (Heidelberg) | participant | 742˙000.00 |
| 7 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 597˙280.00 |
| 8 |
NANOPET PHARMA GMBH
Organization address
address: Robert-Koch-Platz 4 contact info |
DE (Berlin) | participant | 528˙156.00 |
| 9 |
PP-POLYMER AB
Organization address
address: KROSSGATAN 15 contact info |
SE (VALLINGBY) | participant | 431˙899.00 |
| 10 |
DIACOATING GMBH
Organization address
address: MITTERWEG 24 contact info |
AT (INNSBRUCK) | participant | 374˙926.00 |
| 11 |
KOMET RHOBEST GMBH
Organization address
address: Exlgasse 20a contact info |
AT (Innsbruck) | participant | 367˙981.00 |
| 12 |
TOPASS GMBH
Organization address
address: DRAKESTRASSE 42 contact info |
DE (Berlin) | participant | 364˙272.00 |
| 13 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 357˙680.00 |
| 14 |
OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN
Organization address
address: DR. IGNAZ SEIPEL-PLATZ 2 contact info |
AT (WIEN) | participant | 327˙667.86 |
| 15 |
UNIVERSITAET INNSBRUCK
Organization address
address: INNRAIN 52 contact info |
AT (INNSBRUCK) | participant | 261˙757.14 |
| 16 |
JOHNSON & JOHNSON MEDICAL GMBH
Organization address
address: Robert Koch Strasse 1 contact info |
DE (Norderstedt) | participant | 129˙883.00 |
| 17 |
EVONIK INDUSTRIES AG
Organization address
address: RELLINGHAUSER STRASSE 1-11 contact info |
DE (ESSEN) | participant | 80˙258.00 |
| 18 |
Nome Ente NON disponibile
Organization address
address: Uhlandstr. 16 contact info |
DE (Seligenstadt) | participant | 51˙903.41 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The goal of VascuBone is to develop a “tool box” for bone regeneration, which on one hand fulfils basic requirements and on the other hand is freely combinable with what is needed in the respective patient’s situation. The tool box will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the specific medical need. This tool box will be used to develop translational approaches for regenerative therapies of three different types of bone defects. The chosen bone diseases differ in their requirements, to ensure a successful implementation and translation. Additionally this implementation strategy is characterized by high complexity to remove bottlenecks and limitations of bone regeneration identified in the clinical setting. Therefore definite quality criteria have to be evaluated concerning an optimal stem cell source/subpopulation as well as GF concentrations and their bioactivity in vivo. Furthermore quantitative evaluation will focus on the definition of differences between stem cell populations responsible for bone regeneration in young and old people, as a prerequisite for the development of regenerative therapies for the ageing European society. Considering a successful and prompt approval of the biomaterial, for each clinical application a minimum of modification steps in daily routine must be identified. The road map of the project and clinic trials contains pre-determined milestones, to ensure efficacy, safety, and immunological acceptance of the implant. The efficacy is quantified by high innovative MRI and PET/CT technology which is able to demonstrate the regenerative effect of biomaterials and cells in vivo. Based on the clinical data the proposal as “Advanced Therapeutical Medicinal Product” will be submitted to the European Medicines Agency at the end of the project.'
Introduzione (Teaser)
Regenerative medicine is a promising avenue for treating or repairing damaged tissues. A European consortium has decided to develop a 'toolbox' to engineer bone implants that can regenerate bone defects.